RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives.
RedHill applies innovation, focus and a collective mindset of delivering on our promises in building a company primarily focused on U.S commercialization and development of drugs for gastrointestinal, infectious and oncologic diseases.
RedHill’s proven commercial team with a focused operating model promotes the FDA-approved gastrointestinal therapies Rebyota®, for the prevention of recurrence of C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection, and Clenpiq®, a low-volume oral solution bowel preparation for colonoscopy in adults and pediatric patients ages 9 years and older.
We have also built a diversified R&D pipeline of proprietary mid-to-late-stage clinical development drug candidates addressing major unmet medical needs.